Rosuvastatin and Evolocumab for Coronary Artery Disease

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT05984953
Status
Completed

Conditions

  • Coronary Artery Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • statin — DRUG
    40 mg of rosuvastatin daily for 8-12 weeks
  • evolocumab — DRUG
    140 mg evolocumab every 2 weeks (26 weeks)

Study Details

The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the catheterization laboratory during the following time-period: 8/1/2013-4/14/2015 and 5/4/2021 - 10/28/2022.

Key Dates

Start date
Aug 1, 2013
Status verified
Aug 2023
Primary completion
Oct 28, 2022
Completion
Oct 28, 2022

Study Design

Enrollment
195 participants (actual)

Arms

  • Arm: Statin
    85 patients treated with statin
  • Arm: Evolocumab
    110 patients treated with evolocumab in addition to statin or evolocumab alone

Primary Outcome Measure

Expression levels of mRNA in blood cells [ Time Frame: 18 month ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai HospitalNew YorkNew York10029-

Find similar trials in New York, NY

By research site
Mount Sinai Hospital· New York, NY

Related Studies